

Amendments to the Claims:

This listing of claims replaces all prior versions and listings of claims in the application:

Listing of Claims:

1. (Currently amended) A method for treating a bone condition associated with excessive resorption or breakdown of bone tissue, comprising administering to a patient in need thereof ~~an~~ effective amount of FGF-8, FGF-8 analog, or a FGF-8 agonist, wherein the FGF-8 agonist comprises an amino acid sequence at least 90% identical to the amino acid sequence of SEQ ID NO: 1, 2, or 3, or a fragment thereof comprising at least 10 amino acids of the sequence, and wherein FGF-8 or the FGF-8 analog is administered in an amount effective to treat the bone condition in the patient.
2. (Currently amended) The method of claim 1, wherein FGF-8 is administered, and wherein the amino acid sequence of FGF-8 is SEQ ID NO: 1, 2, or 3.
3. (Currently amended) The method of claim 1, wherein the FGF-8 agonist is administered, and wherein the FGF-8 agonist comprises a fragment or the entirety of the amino acid sequence of SEQ ID NO: 1, 2, or 3.
4. (Original) The method of claim 3, wherein the fragment is less than 50 amino acids of SEQ ID NO: 1, 2, or 3.
5. (Currently amended) The method of claim 1, wherein the FGF-8 agonist is administered, and wherein the FGF-8 agonist comprises an amino acid sequence that is at least ~~[[60%]]~~ 95% identical to SEQ ID NO: 1, 2, or 3.

6. (Currently amended) The method of claim 1, wherein the FGF-8 agonist is administered, and wherein the FGF-8 agonist comprises SEQ ID NO: 1, 2, or 3 with up to 14 conservative amino acid substitutions.

7. (Currently amended) A method for increasing or maintaining bone density, comprising administering to a subject in need thereof an effective amount of FGF-8, FGF-8 analog, or a FGF-8 agonist, wherein the FGF-8 agonist comprises an amino acid sequence at least 90% identical to the amino acid sequence of SEQ ID NO: 1, 2, or 3, or a fragment thereof comprising at least 10 amino acids of the sequence, and wherein FGF-8 or the FGF-8 analog is administered in an amount effective to increase or maintain bone density in the subject.

8. (Currently amended) The method of claim 7, wherein FGF-8 is administered, and wherein the amino acid sequence of FGF-8 is SEQ ID NO: 1, 2, or 3.

9. (Currently amended) The method of claim 7, wherein the FGF-8 agonist is administered, and wherein the FGF-8 agonist comprises a fragment or the entirety of the amino acid sequence of SEQ ID NO: 1, 2, or 3.

10. (Original) The method of claim 9, wherein the fragment is less than 50 amino acid residues of SEQ ID NO: 1, 2, or 3.

11. (Currently amended) The method of claim 7, wherein the FGF-8 agonist is administered, and wherein the FGF-8 agonist comprises an amino acid sequence that is at least [[60%]] 95% identical to SEQ ID NO: 1, 2, or 3.

12. (Currently amended) The method of claim 7, wherein the FGF-8 agonist is administered, and wherein the FGF-8 agonist comprises SEQ ID NO: 1, 2, or 3 with up to 14 conservative amino acid substitutions.

13.-18. (Canceled)

19. (Withdrawn) An article of manufacture comprising:

a vessel containing FGF-8, FGF-8 analog, or a FGF-8 agonist; and
written instructions for use of FGF-8, FGF-8 analog, or a FGF-8 agonist for treatment of
a bone condition comprising administering an effective amount of FGF-8, FGF-8 analog, or
a FGF-8 agonist to a patient.

20. (Withdrawn) An article of manufacture comprising:

packaging material; and
contained within the packaging material, FGF-8, FGF-8 analog, or a FGF-8 agonist;
wherein the packaging material comprises a label that indicates that FGF-8, FGF-8 analog, or
a FGF-8 agonist can be used for treating a bone condition in a patient.

21. (Currently amended) A method for treating ~~or preventing~~ osteoporosis, osteopenia, bone
defects, or osteogenesis imperfecta, comprising:

administration to a subject in need thereof ~~an effective amount of FGF-8, FGF-8 analog,~~
or a FGF-8 agonist, wherein the FGF-8 agonist comprises an amino acid sequence at least 90%
identical to the amino acid sequence of SEQ ID NO: 1, 2, or 3, or a fragment thereof, wherein
the fragment thereof comprises at least 10 amino acids of the sequence, and wherein FGF-8 or
the FGF-8 analog is administered in an amount effective to treat the osteoporosis, osteopenia,
bone defects, or osteogenesis imperfecta in the subject.

22. (Withdrawn) A composition comprising FGF-8, FGF-8 analog, or FGF-8 agonist and a
pharmaceutically acceptable carrier.

23. (New) The method of claim 21, wherein FGF-8 is administered, and wherein the amino
acid sequence of FGF-8 is SEQ ID NO: 1, 2, or 3.

24. (New) The method of claim 21, wherein the FGF-8 agonist is administered, and wherein the FGF-8 agonist comprises a fragment or the entirety of the amino acid sequence of SEQ ID NO: 1, 2, or 3.

25. (New) The method of claim 24, wherein the fragment is less than 50 amino acids of SEQ ID NO: 1, 2, or 3.

26. (New) The method of claim 21, wherein the FGF-8 agonist is administered, and wherein the FGF-8 agonist comprises an amino acid sequence that is at least 95% identical to SEQ ID NO: 1, 2, or 3.

27. (New) The method of claim 21, wherein the FGF-8 agonist is administered, and wherein the FGF-8 agonist comprises SEQ ID NO: 1, 2, or 3 with up to 14 conservative amino acid substitutions.